Cardiology

A dual-chamber wireless pacemaker provides reliable performance over three months, bolstering evidence for this new pacemaker option, according to results from a multi-center, international clinical trial co-led by a Weill Cornell Medicine and NewYork-Presbyterian investigator.

A clinical trial led by Weill Cornell Medicine investigators showed that a nasal spray that patients administer at home, without a physician, successfully and safely treated recurrent episodes of a condition that causes rapid abnormal heart rhythms. 

An American Heart Association (AHA) Presidential Advisory, co-authored by a committee including the dean of Weill Cornell Medicine, outlines an ambitious plan to increase rigorous research on initiatives aimed at providing food as medicine for chronic conditions.

The program has prepared Weill Cornell Medicine faculty members to grow into institutional leaders. 

Dr. Jonathan Weinsaft, an esteemed physician-scientist who focuses on clinical research and cardiovascular imaging, has been appointed chief of the Greenberg Division of Cardiology at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center, effective July 1.

Cancers often release molecules into the bloodstream that pathologically alter the liver, shifting it to an inflammatory state, causing fat buildup and impairing its normal detoxifying functions.

Two Weill Cornell Medicine faculty members, Dr. David Lyden and Dr. Harel Weinstein have been elected fellows of the American Association for the Advancement of Science (AAAS).

NewYork-Presbyterian is expanding its renowned heart transplant program, one of the largest and most experienced heart transplant programs in the nation, and increasing access to its world-class heart failure care.

COVID-19 may bring high risks of severe disease and death in many patients by disrupting key metabolic signals and thereby triggering hyperglycemia, according to a new study from researchers at Weill Cornell Medicine and NewYork-Presbyterian. 

Tiny packets called extracellular vesicles and particles (EVPs), released by cancer and immune cells, contain specific proteins that may serve as reliable biomarkers for diagnosing early-stage cancer, according to investigators at Weill Cornell Medicine and Memorial Sloan Kettering.

A protein that breast, lung and other cancers use to promote their spread—or metastasis—to the brain, has been identified by a team led by Weill Cornell Medicine and New York-Presbyterian investigators. The protein, CEMIP, will now be a focus of efforts to predict, prevent and treat brain metastases, which are a frequent cause of cancer deaths.

Atrial fibrillation is a condition that affects as many as 6.1 million Americans and is characterized by an irregular, often rapid heart rate caused by a misfiring of electrical impulses.